Indium (In111) Oxinat Curiumpharma (Indium (111in) Oxine)

Indium (In111) Oxinat is used in nuclear medicine to visualize infection‑related processes through leukocyte labeling.

• Leukocyte scintigraphy for detection of infection: provides whole‑body imaging of bacterial or fungal foci by tracking radiolabelled white blood cells.
• Inflammation imaging: highlights areas of active inflammation in soft tissue, bone, or vascular structures.
• Evaluation of prosthetic joint infection: helps differentiate septic from aseptic loosening of joint implants.

• Indium‑111 oxine forms a lipophilic complex that readily penetrates leukocyte membranes. Inside the cell, the oxine dissociates and the indium‑111 ion binds intracellular proteins, remaining trapped. The bound radioisotope emits gamma photons detectable by a gamma camera, allowing clinicians to locate and quantify sites of infection or inflammation based on the distribution of labelled leukocytes.

Adverse reactions are generally related to the radiopharmaceutical nature of the product and the injection procedure.

Common Side Effects

• Transient flushing or warmth at the injection site
• Mild nausea or vomiting
• Headache
• Injection‑site pain or bruising
• Temporary mild leukopenia

Serious or Rare Side Effects

• Allergic or anaphylactic reaction
• Severe radiation‑induced leukopenia or thrombocytopenia
• Significant hypersensitivity with rash or bronchospasm
• Unexpected organ radiation injury
• Acute hemolysis (very rare)

Use of Indium (In111) Oxinat requires careful assessment of patient condition and handling of radioactive material.

• Pregnancy: avoid unless the diagnostic benefit outweighs fetal radiation risk.
• Breastfeeding: discontinue breastfeeding for an appropriate period after administration.
• Renal impairment: evaluate radiation dose and clearance.
• Concurrent radiopharmaceuticals: avoid overlapping scans that could interfere with image interpretation.
• Radiation safety: follow institutional protocols for shielding, waste disposal, and personnel monitoring.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Indium (In111) Oxinat may interact with other agents that affect leukocyte function or radiation exposure.

Major Interactions (Avoid)

• Co‑administration of other gamma‑emitting radiopharmaceuticals that overlap indium‑111 energy peaks.
• High‑dose chelating agents (e.g., DTPA) that can strip indium from labelled cells.
• Therapeutic steroids that markedly suppress leukocyte activity.

Moderate Interactions (Monitor Closely)

• Anticoagulants may increase bleeding risk at the injection site.
• Immunosuppressive drugs can reduce labeling efficiency and image quality.
• Iodinated contrast agents used in CT may affect subsequent scintigraphic interpretation.
• Beta‑blocking agents may alter peripheral blood flow, influencing cell distribution.
• High‑dose vitamin C supplements could theoretically affect oxidative stability of the radiolabel.